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Abstract
Objective To evaluate the reliability of risk of bias assessments based
on published trial reports, for determining trial inclusion in meta-analyses.
Design Reliability evaluation of risk of bias assessments.
Data sources 13 published individual participant data (IPD)
meta-analyses in cancer were used to source 95 randomised controlled
trials.
Review methods Risk of bias was assessed using the Cochrane risk
of bias tool (RevMan5.1) and accompanying guidance. Assessments
were made for individual risk of bias domains and overall for each trial,
using information from either trial reports alone or trial reports with
additional information collected for IPD meta-analyses. Percentage
agreements were calculated for individual domains and overall
(<66%=low, ≥66%=fair, ≥90%=good). The two approaches were
considered similarly reliable only when agreement was good.
Results Percentage agreement between the twomethods for sequence
generation and incomplete outcome data was fair (69.5% (95%
confidence interval 60.2% to 78.7%) and 80.0% (72.0% to 88.0%),
respectively). However, percentage agreement was low for allocation
concealment, selective outcome reporting, and overall risk of bias (48.4%
(38.4% to 58.5%), 42.1% (32.2% to 52.0%), and 54.7% (44.7% to
64.7%), respectively). Supplementary information reduced the proportion
of unclear assessments for all individual domains, consequently
increasing the number of trials assessed as low risk of bias (and therefore
available for inclusion in meta-analyses) from 23 (23%) based on
publications alone to 66 (66%) based on publications with additional
information.
ConclusionsUsing cancer trial publications alone to assess risk of bias
could be unreliable; thus, reviewers should be cautious about using them
as a basis for trial inclusion, particularly for those trials assessed as
unclear risk. Supplementary information from trialists should be sought
to enable appropriate assessments and potentially reduce or overcome
some risks of bias. Furthermore, guidance should ensure clarity on what
constitutes risk of bias, particularly for the more subjective domains.
Introduction
The quality of the studies that contribute to a systematic review
will to some extent determine the validity and reliability of the
results of that review. Various tools are available to assess the
quality of trials, often in terms of allocation concealment and
blinding.1 2 Indeed, assessments of trial quality or risk of bias
have become a common feature of systematic reviews, being a
requirement of publication in peer reviewed journals adhering
to PRISMA guidelines.3
The Cochrane Handbook4 states that because the ability to
measure the true bias (or even the true risk of bias) is limited,
then the possibility to validate a tool to assess that risk is also
limited. Nevertheless, authors of Cochrane systematic reviews
are required to use the Cochrane risk of bias tool (RevMan5.1)5
to appraise risk of bias for randomised controlled trials across
six domains relating to selection, performance, detection,
attrition, and outcome reporting biases, and to combine these
assessments to evaluate the risk of bias for individual trials. The
current version of the Cochrane handbook4 also suggests that
reviewers should “take risk of bias into account” in
meta-analyses. One recommendation is that studies at “low”
and “unclear” risk of bias should not be combined in
meta-analyses, unless authors “provide specific reasons for
believing that these studies are likely to have been conducted
in a manner that avoided bias.” Alternatively, studies judged to
be at high or unclear risk of bias could be “given reduced weight
in meta-analyses,” compared with studies at low risk of bias.6
However, since formal statistical methods are not yet
recommended for routine use, authors are guided to “restrict
meta-analyses to studies at low (or lower) risk of bias, or to
stratify studies according to risk of bias.”
The vast majority of Cochrane (and other) systematic reviews
is based on information extracted from the publications of
eligible studies. Therefore, most risk of bias assessments are
similarly based on trial publications. However, trial quality is
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not necessarily well represented in publications.7 While
initiatives such as CONSORT8 9 should improve quality, many
trials included in systematic reviews may have been published
before the uptake of CONSORT guidelines; been published in
journals that are yet to implement CONSORT recommendations;
or, indeed, not been published at all.
By conducting systematic reviews based on individual
participant data (IPD), as well as collating full datasets for each
of the included trials, our group has obtained copies of trial
protocols and other information about the design and conduct
of included trials directly from trial investigators, rather than
relying solely on published information. This approach has
allowed a greater insight into any potential biases in those trials.
We therefore aimed to use this additional information to evaluate
the reliability of risk of bias assessments based on trial
publications alone for trials included in our meta-analysis. A
further aim was to investigate the effect of any differences in
the risk of bias judgments for individual trials on resulting
meta-analyses.
Methods
Thirteen completed IPDmeta-analyses of treatments for cancer,
published by our group, were used as a source of randomised
controlled trials.10-21 So that risk of bias assessments could be
conducted, trials had to be published either in full or as an
abstract, and a copy of the trial protocol or forms detailing trial
design completed by trialists (or both) had to be available.
Therefore, unpublished trials and those for which we had neither
protocols nor forms were necessarily excluded.
Blinding of the treatment allocations is rarely feasible for
randomised controlled trials of cancer treatments, and because
the primary outcome of the studies (and indeed for all of the
included IPD reviews) is often overall survival, blinded outcome
assessments are uncommon and unlikely to introduce bias. We
therefore applied an assessment of low risk of bias to the
domains of blinding of participants and personnel and blinding
of outcome assessment for all included trials. Two authors (SB
and CLV) carried out assessments of risk of bias for the
individual domains relating to allocation concealment, sequence
generation, incomplete outcome data, and selective reporting
of outcomes using the Cochrane risk of bias tool5 and guidance
from the Cochrane handbook.4
Data relating to individual domains were first extracted from
the trial publications so that assessments of risk of bias could
be made. The process was then repeated using the publications
plus additional information collected as part of the IPD process
(table 1⇓). Because our IPD meta-analyses spanned a period of
almost 20 years, we had not designed data collection forms with
risk of bias assessment in mind; subsequently, information
relating to the individual domains was not consistently
requested. Therefore, we sought details directly from the IPD
supplied on the numbers of patients randomised or analysed for
assessment of attrition bias and on the outcomes available, to
establish selective outcome reporting bias. If assessments of
any of the individual domains by the two authors disagreed,
they were resolved by discussion and consensus, sometimes
involving a third author (JFT), in order to obtain a single set of
assessments for each trial for the two approaches.
To obtain an overall risk of bias assessment for each trial, the
authors agreed a priori on three key domains: sequence
generation, allocation concealment, and incomplete outcome
data. These domains were thought most likely to represent
potential biases within trials. For a trial to be classified as low
risk of bias, all three key domains had to be judged low risk. If
one or more of these domains was classed as unclear, the overall
judgement for the trial was also unclear; similarly, if one or
more of the domains was assessed as high risk of bias, the trial
was also deemed to be at high risk of bias.
To assess the reliability of basing assessments on publications
alone, we calculated percentage agreements and associated 95%
confidence intervals between assessments based on the two
approaches for each individual domain and at the trial level.
Agreement of less than 66%was considered to be low, whereas
agreement of 66% or more was categorised as fair.22 However,
for the two approaches to be considered similarly reliable, a
high level of agreement, in the order of 90%, was regarded as
appropriate.
Finally, we explored the potential effect of the trial level
assessments on meta-analyses by comparing the number and
proportion of trials assessed as low risk of bias and therefore
considered appropriate for inclusion in each of the 13 IPD
meta-analyses using the two approaches.
Results
We found 95 randomised controlled trials from 13 completed
and published IPD meta-analyses for which publications,
protocols, or completed forms were available. Other trials
included in these 13 meta-analyses were not available for this
study, either because they were unpublished, or because forms
or protocols had not been collected (fig 1⇓). Of 95 available
trials, 88 (93%) were published in full and seven (7%) had been
presented as conference abstracts. Risk of bias assessments,
using both approaches, were completed for all 95 studies.
Risk of bias assessments for individual
domains
Selection bias
Based on published information alone, 42 (44%) trials were
judged at low risk of bias for sequence generation compared
with 69 (73%) when additional information from protocols and
forms was used. This difference was largely due to a reduction
in the number of trials classified as unclear risk of bias (53
(56%) from publications alone decreasing to 26 (27%) when
additional information was used). The percentage agreement
between the two approaches was fair (69.5%, 95% confidence
interval 60.2% to 78.7%; table 2⇓, fig 2⇓).
For allocation concealment, 40 (42%) trials were assessed as
having low risk of bias using publications only compared with
89 (93%) when using additional information. Again, this was
due to a reduction in the proportion of unclear classifications,
from 55 trials (58%) based on publications alone to only six
trials (7%) based on the additional information. The percentage
agreement between the two approaches was low (48.4%, 95%
confidence interval 38.4% to 58.5%; table 2, fig 3⇓). There were
no assessments of high risk of bias for either of these domains
using either approach.
Performance and detection bias
Although none of the included trials was blinded, for the primary
outcome of overall survival, we assessed both performance and
detection bias as low risk for all trials and using both approaches
for reasons outlined above.
Attrition bias
To evaluate attrition bias, on the basis of whether the outcome
data were incomplete or not, the authors had to establish a rule
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of thumb to ensure consistency between assessments. Trials
were assessed as low risk of bias if less than 10% of patients
were excluded overall and if similar proportions were excluded
from both arms. Trials were judged as high risk of bias if there
were considerable imbalances between arms or if more than
10% of randomised patients were excluded from the analysis.
Based on publications only, 74 trials (78%) were assessed as
low risk, compared with 90 (95%) using the additional
information. Eleven trials (12 %) were judged to be at unclear
risk based on publications alone compared with only one trial
(1%) when the additional information was used. Ten further
trials (11%) were at high risk of attrition bias from the
publications alone compared with only four trials (4%) using
additional information. Overall, the percentage agreement
between the two approaches was fair (80%, 95% confidence
interval 72.0% to 88.0%; table 2, fig 4⇓).
Outcome reporting bias
Based on the publications only, 37 trials (39%) were judged to
be at low risk of outcome reporting bias compared with 90 trials
(95%) when protocols and forms were used. Ten trials (11%)
were assessed as unclear risk of bias based on publications alone
whereas with additional information, no trials were judged
unclear. The number of trials at high risk of bias also fell from
48 (51%) based on publications to five (5%) with additional
information. The percentage agreement between the two
approaches was low (42.1%, 95% confidence interval 32.2%
to 52.0%; table 2, fig 5⇓).
Overall risk of bias assessments for individual
trials
Based on publications only, 23 trials (24%) were classified as
low risk of bias compared with 64 trials (67%) based on
publications supplemented with additional information. This
was largely due to the reduction in trials classified as unclear
risk of bias from 70 (74%) using publications alone to 31 (33%)
using protocols and forms. There were no trials at high risk of
bias with the use of additional information compared with two
trials (2%) with publications only. The percentage agreement
between the two approaches to judging overall risk of bias was
low (54.7%, 95% confidence interval 44.7% to 64.7%; table 2,
fig 6⇓).
Just over half the trials (n=54, 57%) were published up to or
including 1996, when the original CONSORT statement was
published,8 with the remainder (n=41, 43%) published from
1997 onwards.We found a reduction in the proportion of unclear
risk of bias assessments (χ2=5.52, P=0.02) for trials published
after CONSORT (≥1997, n=25, 61%) compared with those
published before CONSORT (≤1996, n=45, 83%).
Potential impact on meta-analyses
Overall, 23 trials (23%) were assessed as low risk of bias based
on publications alone; however, with additional information,
66 trials (66%) were classified as low risk of bias (table 3⇓).
Had the 13 meta-analyses included only those trials at low (or
lower) risk of bias (as recommended in the Cochrane
Handbook), and if assessments were based on publications
alone, five meta-analyses (38%) could not be undertaken,
because none of the included trials were judged to be at low
risk of bias. If additional information was used, the number of
trials assessed at low risk of bias (and therefore available for
inclusion) was increased for all except for one meta-analysis
(table 3), largely because of better ascertainment of sequence
generation (fig 2) and allocation concealment (fig 3) from trial
protocols or forms. Therefore, the additional information clearly
would have improved the power, precision, and reliability of
the results obtained in all but one of the meta-analyses. For
example, in one meta-analysis in our sample, the inclusion of
only trials judged as having low risk of bias from publications
limited the meta-analysis to only two of 14 eligible trials (338
of a total of 3995 randomised patients), and—perhaps not
surprisingly—results based on this limited subset of the trials
were inconclusive.
Discussion
By comparing assessments of risk of bias of randomised
controlled trials in cancer made from publications with those
using supplementary information, including IPD, our study has
gone some way towards validating the Cochrane risk of bias
tool, since access to that additional information and data enables
us to get closer to the true risk of bias of individual studies.
Appraising trial quality should inevitably be a key aspect of any
well conducted systematic review; however, our results indicate
that basing such assessments on publications alone is probably
not appropriate. In general, agreement between the two
approaches was low, and for all but one of the individual
domains (attrition bias) and the overall assessment for the trial,
agreement fell far short of “ideal.”
Comparison with other studies
These findings are supported by a recent study that showed an
increased proportion of “adequate” quality assessments for
sequence generation and allocation concealment in 429
randomised controlled trials in cancer when trial protocols were
used alongside publications.23 A further study found that the
assessment of selective outcome reporting bias was changed
for three of five trials for which protocols were obtained in a
systematic review of treatments for asthma.24 Our results show
that when all information was taken into account, the majority
of trials assessed as unclear risk of bias from publications alone
were actually at low risk of bias. Therefore, current advice
regarding trials at unclear risk of bias might not be appropriate.
Our study indicates that deficiencies with the reporting of trials
does not necessarily reflect deficiencies in trial quality, and that
poor reporting can often be the cause of inappropriate
evaluations of risk of bias, in particular for selective outcome
reporting bias.
Even for trials from the post CONSORT8 era, more than 60%
were deemed to have unclear risk of bias using publications
alone. Although wider adoption of CONSORT and greater
implementation of its requirements by journal editors, peer
reviewers, and trial authors might improve the ability to judge
a trial’s quality from its publication, some trials will inevitably
remain unreported, or be reported only in the grey literature.
Although in due course, CONSORT for abstracts25 could go
some way to improving this reporting situation, risk of bias
assessments for unpublished trials remain difficult. Their
inclusion in systematic reviews, however, remains fundamental
to reducing the effect of reporting biases.26-29
Strengths and limitations of study
Assessing risk of bias was particularly difficult for the more
subjective domains. Although the two authors made consistent
judgments for allocation concealment and sequence generation,
discrepancies were more common for attrition bias such that a
rule around cut-off rates of attrition or patient exclusions was
established by the authors to ensure consistency of assessments.
Clearly, a different cut-off would lead to different results.
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Consistent assessment of selective outcome reporting bias30 31
was also problematic, possibly because it requires reviewers to
consider how the reporting of trial level outcomes affects the
review as a whole, and is not solely a within trial judgment, as
for the other domains. Our findings are similar to those
previously reported,32 in which low inter-rater agreements were
identified for individual domains, in particular, incomplete
outcome data and selective outcome reporting. The authors
subsequently demonstrated improved agreement, partly because
of their use of specifically developed decision rules for
completing risk of bias assessments.24 The 95 randomised
controlled trials included in the present study clearly represented
a selected group of trials. All of the included trials were cancer
trials that, in general, tended to be fairly well conducted. Also,
we applied the risk of bias assessment to overall survival—an
objective outcome that is commonly well reported—rather than
considering all possible outcomes as is recommended. Our
results could have therefore represented an optimistic view of
the reliability of the risk of bias assessments using published
information alone, particularly in relation to incomplete outcome
data and selective outcome reporting. Furthermore, the
additional information supplied was sometimes limited because
the data collection forms obtained in some of the older IPD
meta-analyses did not request specific details on methods of
sequence generation and planned trial outcomes. The older trial
protocols were also often ambiguous with regard to the
assessment of some of the required domains. Therefore, even
with additional information, around a third of the included
studies were classified as unclear risk of bias. Clearly, forms
purposely designed to collect specific information would help
reviewers reach appropriate judgments regarding risk of bias,
in particular for those trials with inadequate information
published.
In an IPD meta-analysis, we routinely checked the integrity of
the randomisation and allocation concealment for the IPD
supplied33 such that, in reality, none of the 95 trials included in
this study was excluded from our meta-analyses for being at
unclear or high risk of these selection biases. If uncertainty
about trial design or conduct could not be adequately
resolved—for example, if many patients were excluded from
the trial and we were not able to reinstate them, meaning that
the trial potentially had a high risk of attrition bias—we would
report this and conduct sensitivity analyses, thus using risk of
bias to more fittingly influence the meta-analyses. However,
this approach depended on obtaining a reliable assessment of
risk of bias.
Conclusions
Our results have shown that obtaining additional information
about allocation concealment, sequence generation methods,
and blinding can improve the accurate ascertainment of
selection, performance, and detection biases. This approach can
therefore ensure that trials are not inappropriately excluded from
meta-analyses, simply because of inadequate reporting.
Information can be sought directly from trialists, trial protocols,
or trial registries.34 If resources are limited, the greatest attention
could be given to those trials with the most limited information,
such that appropriate assessments can be made for all eligible
trials. Furthermore, obtaining information regarding numbers
of patients randomised or planned outcome assessments may
also overcome deficiencies in the reporting of trials. Indeed, if
summary results are obtained, it may also be possible to
overcome the risk of attrition or selective outcome reporting
bias completely within a meta-analysis.
Guidance needs to be clear on what constitutes risk of bias,
particularly for the more subjective bias domains. Advice to
exclude trials at unclear risk of bias could be misleading.
Certainly, reviewers should be cautious about basing decisions
about trial inclusion on the risk of bias, particularly if
assessments have been obtained using publications alone, which
may lead to good evidence being disregarded in meta-analyses.
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Tables
Table 1| Sources of information from which data for individual risk of bias domains were obtained
Sources of information used to extract data relating to risk of bias (where available)
Risk of bias domain/information sought Individual patient dataData collection formsTrial protocolTrial publication
Selection bias
NoYesYesYesMethod of allocation concealment
NoYesYesYesMethod of sequence generation
Attrition bias
YesYesNoYesNumber of patients randomised (by arm)
YesYesNoYesNumber of patients excluded (by arm)
YesNoNoYesReasons for exclusion
Selective outcome reporting bias
NoYesYesYesOutcomes planned
YesYesNoYesOutcomes reported
YesYesNoYesOutcomes available
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Table 2| Outcomes and comparison of risk of bias assessments
Percentage
agreement (%; 95%
CI)
No of assessments based on publications plus
supplementary information
No of assessments based on publications onlyRisk of bias domain
HighUnclearLowHighUnclearLow
69.5 (60.2 to 78.7)0266905342Sequence generation
48.4 (38.4 to 58.5)068905540Allocation concealment
80.0 (72.0 to 88.0)4190111074Incomplete outcome data
42.1 (32.2 to 52.0)5090481037Selective outcome
reporting
54.7 (44.7 to 64.7)0316427023Overall risk of bias for trial
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Table 3| Studies assessed as low risk of bias for individual meta-analyses
Risk of bias assessmentNo of trials
with
completed
assessmentsMeta-analysis
Publications plus extra informationPublications only
HighUnclearLowHighUnclearLow
00140122141
02603582
01203033
02616184
01102025
03615396
02103037
06207188
03203259
041101051510
071001341711
024060612
011020213
034 (34%)66 (66%)2 (2%)75 (75%)23 (23%)100Total
Data are no of assessments.
*Percentage of total number of trials. Total number of trials (n=100) is greater than the total number of unique trials in the sample (n=95), because some trials
contributed data to more than one meta-analysis).
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Figures
Fig 1 Flowchart of trial sample selection
Fig 2 Comparison of assessments for sequence generation between publications only and publications plus additional
information
Fig 3 Comparison of assessments for allocation concealment between publications only and publications plus additional
information
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Fig 4 Comparison of assessments for incomplete outcome data between publications only and publications plus additional
information
Fig 5Comparison of assessments for selective outcome reporting between publications only and publications plus additional
information
Fig 6Comparison of assessments for overall risk of bias for trials between publications only and publications plus additional
information
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